Sylviane is a broad based scientist of international reputation. She has extensive leadership, scientific research and drug discovery experience in the pharmaceutical industry.

Sylviane started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department for the Laboratoires Fournier (Dijon, France). Part of her team’s responsibilities was to explore the mechanism of action of two immunosuppressants in clinical development (phase III and II). In June 2000 she joined Organon Laboratories Ltd. (Newhouse, Scotland) as team leader for Cardiovascular Lead Discovery activities. She was responsible for managing a portfolio of early drug discovery projects in Cardiovascular from target identification and validation to lead optimisation.

In 2005, she assumed responsibility for the compound repository store and became Head of Assay and Compound Technology group. In November 2007 Schering-Plough acquired Organon, then two years later; Schering-Plough was acquired by Merck. From 2007 until 2010 she was Head of Global Compound repository and in vitro Screening. Throughout these company mergers Sylviane worked closely alongside her USA colleagues regarding compound library integration and inter-site compound distribution. She has also been involved in a number of outsourcing projects regarding compound management, chemistry and assay development with CROs mainly based in the Far East.

Sylviane attained her Masters in Physiology and PhD in Cellular and Molecular Biology from the University of Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, Grenoble, France and the University of Manchester, UK under the Wellcome Trust International Fellowship.

DOWNLOAD PUBLICATIONS LIST (PDF)